LONDON, Apr 6: AstraZeneca’s experimental rheumatoid arthritis pill fostamatinib met only one of two goals in a late-stage clinical trial, leaving the future of one of the group’s few advanced pipeline products uncertain. Fostamatinib is a potential competitor to injectable drugs like AbbVie’s Humira and a new pill from Pfizer called Xeljanz in a 20 billion dollars plus market. Disappointing results from earlier tests, however, mean investor hopes for the medicine are low. (agencies)
Follow our WhatsApp channel